Less Ads, More Data, More Tools Register for FREE

Pin to quick picksVRP.L Regulatory News (VRP)

  • There is currently no data for VRP

Interim Results

29 Sep 2006 09:28

Verona Pharma PLC29 September 2006 VERONA PHARMA PLC (Formerly known as ISIS RESOURCES PLC) Interim Report For the six months ended 30 June 2006 CHAIRMAN'S STATEMENT Dear Shareholders, It is with pleasure that I join the Board of Verona Pharma plc (the "Company")as Chairman following the Company's acquisition of Rhinopharma Limited ("Rhinopharma"). During the six month period ended 30 June 2006, the Company entered into a headsof agreement to acquire Rhinopharma. Subsequent to this period, on 18 September2006, shareholders approved the acquisition of Rhinopharma (the "Acquisition")together with a change of name of the Company from Isis Resources plc. Following the Acquisition, the Company's objective is to build a businessrecognised for the discovery and development of new drugs for the treatment ofallergic rhinitis (hay fever) and other chronic respiratory and inflammatorydiseases. The drugs currently under development by Rhinopharma together withthe experience, track record and network of the Rhinopharma team positions theCompany well to achieve this objective. In conjunction with the Acquisition, the Company completed a placement of51,075,000 new ordinary shares at 4p each to raise £2,043,000, before expenses.The Company was re-admitted to trading on AIM on 19 September 2006. I would like to take this opportunity to thank Craig Burton and Josef El-Raghyfor their contributions to the board and welcome to the board Michael Walker,Trevor Jones and Claire Poll. Together with Stuart Bottomley, the new Directorsare looking forward to leading the Company through this exciting new phase inits development and growth. On behalf of the board, I thank you for your support. Yours faithfully, Clive PageChairman INCOME STATEMENT Six Month Period Incorporation to ended 30 June 2006 30 June 2005 (unaudited) £ (unaudited) £ Note Revenue - -Administration expenses (84,396) (31,518)Other operating income - -Operating loss (84,396) (31,518)Interest income 30,160 12,808Loss before taxation (54,236) (18,710)Taxation - -Loss for the period (54,236) (18,710) Earnings per ordinary shareBasic (pence per share) 7 (0.11) (0.06)Diluted (pence per share) 7 (0.09) (0.05) All transactions arise from continuing operations BALANCE SHEET 30 June 30 June 2006 2005 (unaudited) (unaudited) £ £ Note ASSETS Current assets Trade and other receivables 3 164,188 1,970 Cash and cash equivalents 862,798 1,000,903 Total assets 1,026,986 1,002,873 EQUITY AND LIABILITIES Capital and reserves Share capital 4 50,200 50,000 Share premium 5 903,412 903,745 Other reserves 5 (32,799) 60,503 Retained losses (28,269) (18,710) Total equity 5 892,544 995,538 Current liabilities Trade and other payables 134,442 7,335 Total equity and 1,026,986 1,002,873liabilities CASH FLOW STATEMENT Six Month Period Incorporation to ended 30 June 30 June 2005 2006 (unaudited) (unaudited) £ £ Note Net cash outflow from operating activities 6 (116,971) (26,153) Investing activitiesInterest received 30,160 12,808Net cash from investing activities 30,160 12,808 Financing activities Net proceeds from issuance of ordinary share - 953,745capital Net cash from financing activities - 953,745 Effects of exchange rate changes (32,799) 60,503 Net increase/(decrease) in cash and cash (119,610) 1,000,903equivalentsCash and cash equivalents at the beginning of 982,408 -the periodCash and cash equivalents at the end of the 862,798 1,000,903period NOTES TO THE ACCOUNTS 1 Accounting Policies Basis of accounting The interim financial information for the six months ended 30 June 2006 isunaudited and does not constitute statutory accounts as defined in section 240of the Companies Act 1985. It was approved by the board of Directors on 29September 2006. The financial statements have been prepared under the historical cost conventionand in accordance with International Financial Reporting Standards as adopted bythe European Union. The interim financial information for the six months ended 30 June 2006 has beenprepared pursuant to AIM rule 18 and represents the half-yearly report for thesix months then ended. AIM rule 18 states; "An AIM company must prepare a halfyearly report in respect of the six month period from the end of the financialperiod for which financial information has been disclosed in its admissiondocument and at least every subsequent six months thereafter (apart from thefinal period of six months preceding its accounting reference date for itsauditing accounts.)". Foreign currencies The functional currency of the Company is the United States Dollar ($). Thisrepresents the currency of the primary economic environment in which the companyoperates. Monetary assets and liabilities denominated in foreign currencies aretranslated into $ at rates of exchange ruling at the balance sheet date.Transactions in foreign currencies are recorded at the rate ruling at the dateof the transaction. All differences are taken to the income statement. The interim report has been prepared in sterling (£). Assets and liabilities aretranslated into £ at the rate of exchange ruling at the date of that balancesheet. Income and expenses are translated into £ at the rate ruling at the dateof the transaction. All resulting exchange differences are recognised as aseparate component of equity. 2 Taxation No liability to UK or overseas taxation has arisen during the period and noprovision for deferred tax was considered necessary. 3 Trade and other receivables 30 June 30 June 2006 2005 £ £Other receivables 6,701 1,970Prepayments 157,487 - 164,188 1,970 Prepayments relate to cost of issuing share capital. The shares were allottedafter the year end and the prepayment was transferred to the share premiumreserve in accordance with IAS 32. 4 Called-up share capital 30 June 30 June 2006 2005 £ £Authorised:10,000,000,000 ordinary shares of 0.1p 10,000,000 10,000,000each Allotted, issued and fully paid:50,200,000 ordinary shares of 0.1p each 50,200 50,000 On 24 August 2005, 200,000 options were exercised at 2 pence each. 5 Shareholders' funds and changes in shareholders' equity Share Share Translation Retained capital premium reserve earnings Total £ £ £ £ £ Balance at 1 January 2006 50,200 903,412 - 25,967 979,579Net loss for the period - - - (54,236) (54,236)Exchange adjustments - - (32,799) - (32,799) _________ _________ _________ _________ _________ Balance at 30 June 2006 50,200 903,412 (32,799) (28,269) 892,544 6 Reconciliation of operating loss to net cash outflow from operating activities 30 June 30 June 2006 2005 £ £ Operating loss (84,396) (31,518)(Increase) in receivables (155,270) (1,970)Increase in payables 122,695 7,335 Net cash outflow from operating activities (116,971) (26,153) 7 Earning per share The calculation of the basic loss per share of (0.11) pence (2005: (0.06)pence) is based on a loss of £54,236 to 30 June 2006 and the weighted averagenumber of ordinary shares outstanding of 50,200,000 at 30 June 2006. Thediluted loss per share is based on a weighted average number of sharesoutstanding of 61,000,000 and the loss per share presented. 30 June 30 June 2006 2005 Number Number Basic weighted average number of shares 50,200,000 30,920,635Dilutive share options 10,800,000 3,793,651 Diluted weighted average number of shares 61,000,000 34,714,286 8 Publication of Non-statutory Accounts The financial information set out in this interim report does not constitutestatutory accounts as defined in section 240 of the Companies Act 1985. Theauditors' report on these financial statements was unqualified and did notcontain a statement under Section 237(2) of the Companies Act 1985. 9 Subsequent events The major events subsequent to 30 June 2006 are set out in the Chairman'sStatement. This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
29th Oct 20207:00 amGNWVerona Pharma plc Operational Update and Financial Results for the Three and Nine Months Ended September 30, 2020
28th Oct 202011:01 amGNWVerona Pharma plc : Update on AIM Delisting
23rd Oct 20205:30 pmRNSVerona Pharma
22nd Oct 20207:00 amGNWVerona Pharma to Announce Interim Results for the Three and Nine Months Ended September 30, 2020 and Provide Corporate Update
13th Oct 20207:00 amGNWVerona Pharma to Present Phase 2b COPD Symptom and Quality of Life Data with Ensifentrine at CHEST 2020
23rd Sep 20209:06 amGNWVerona Pharma Initiates Phase 3 Clinical Trials with Nebulized Ensifentrine for the Maintenance Treatment of COPD
21st Sep 20207:00 amGNWIntended Delisting and Cancellation of Ordinary Shares from Trading on AIM
17th Sep 20207:00 amGNWVerona Pharma to Ring the Nasdaq Closing Bell to celebrate $200 million financing
16th Sep 20201:25 pmGNWVerona Pharma Announces Publication of Phase 2b COPD Symptom Data in the International Journal of Chronic Obstructive Pulmonary Disease
8th Sep 20207:00 amGNWVerona Pharma Initiates Pilot Study with pMDI Ensifentrine in U.S. Patients Hospitalized with COVID-19
2nd Sep 20207:00 amGNWVerona Pharma to Present at H.C. Wainwright 22nd Annual Global Virtual Investment Conference
26th Aug 202010:19 amGNWVerona Pharma plc: Grant of RADSUs and PDMR Dealings
24th Aug 20207:00 amGNWVerona Pharma to Present Phase 2b data with Ensifentrine in COPD at the European Respiratory Society International Congress 2020
19th Aug 20207:00 amGNWVerona Pharma Initiates Multiple Dose Part of Phase 2 Clinical Trial with pMDI Formulation of Ensifentrine in COPD
14th Aug 202011:05 amRNSSecond Price Monitoring Extn
14th Aug 202011:00 amRNSPrice Monitoring Extension
14th Aug 20207:00 amGNWVerona Pharma plc Operational Update and Financial Results for the Three and Six Months Ended June 30, 2020
7th Aug 20203:46 pmGNWVerona Pharma plc: TR-1: Standard form for notification of major holdings
4th Aug 20206:13 pmGNWVerona Pharma plc: Issue of Equity, PDMR Dealings & Total Voting Rights
3rd Aug 20207:00 amGNWVerona Pharma Announces August 2020 Virtual Investor Conference Participation
30th Jul 202010:52 amGNWVerona Pharma plc: TR-1: Standard form for notification of major holdings
30th Jul 20207:00 amGNWVerona Pharma to Announce Interim Results for the Three and Six Months Ended June 30, 2020 and Provide Corporate Update
27th Jul 20207:01 amGNWVerona Pharma plc: TR-1: Standard form for notification of major holdings
22nd Jul 20204:50 pmGNWClosing of Financing, Issued Share Capital and Total Voting Rights
17th Jul 20205:47 pmGNWVerona Pharma plc: PDMR Dealings
17th Jul 20207:00 amGNWVerona Pharma Raises $200 Million in Oversubscribed Private Placement and Subscription
6th Jul 20204:04 pmGNWVerona Pharma plc: Issue of Equity and Total Voting Rights
14th May 20207:00 amGNWVerona Pharma Announces FDA Response to End-of-Phase 2 Briefing Package for Ensifentrine in COPD and Outlines Phase 3 ENHANCE Clinical Program
12th May 20201:11 pmGNWDirector/PDMR Shareholding - Grant of Restricted Stock Units, Issue of Equity, Total Voting Rights & PDMR Dealings
1st May 20205:12 pmGNWVerona Pharma Presents Expanded Analysis of Ensifentrine Clinical Data in COPD Maintenance Treatment at the American Thoracic Society 2020 International Conference
30th Apr 20207:00 amGNWVerona Pharma plc: Operational Update and Financial Results for the Three Months Ended March 31, 2020
23rd Apr 20207:00 amGNWVerona Pharma to Announce Financial Results for the Three Months Ended March 31, 2020 and Provide Corporate Update
16th Apr 202012:12 pmGNWVerona Pharma plc: Results of AGM
8th Apr 20207:00 amGNWUpdate on AGM Procedure
31st Mar 20207:00 amGNWVerona Pharma Reports Positive Efficacy and Safety Data with Single Dose pMDI Formulation of Ensifentrine in COPD
20th Mar 202011:28 amGNWVerona Pharma plc: Issue of Equity and Total Voting Rights
17th Mar 20202:06 pmRNSSecond Price Monitoring Extn
17th Mar 20202:01 pmRNSPrice Monitoring Extension
16th Mar 20205:13 pmGNW2019 Annual Report and Accounts and Notice of AGM
5th Mar 20204:01 pmGNWGrant of Restricted Stock Units and PDMR Dealings
27th Feb 20207:00 amGNWVerona Pharma Reports Financial Results for the Full Year Ended December 31, 2019 and Provides Corporate Update
21st Feb 20207:00 amGNWVerona Pharma plc to Announce Financial Results for Full Year Ended December 31, 2019 and Provide Corporate Update
14th Feb 20207:00 amGNWVerona Pharma Announces Publication of Key Phase 2b COPD Data in Respiratory Research
7th Feb 20207:00 amGNWHolding(s) in Company TR-1: Standard form for notification of major holdings
3rd Feb 20207:00 amGNWVerona Pharma Announces Senior Management Changes
28th Jan 20207:00 amGNWVerona Pharma to Present at LSX World Congress 2020
17th Jan 20201:06 pmGNWHolding(s) in Company TR-1: Standard form for notification of major holdings
13th Jan 20204:41 pmRNSSecond Price Monitoring Extn
13th Jan 20204:35 pmRNSPrice Monitoring Extension
13th Jan 20205:00 amGNWVerona Pharma Reports Positive Top-line Data in 4 Week Phase 2b COPD Study with Nebulized Ensifentrine on Top of Tiotropium Therapy

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.